ZCCHC8 inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of zinc finger CCHC-type containing protein 8 (ZCCHC8). ZCCHC8 is a component of the nuclear exosome targeting (NEXT) complex, which is involved in RNA metabolism, particularly in the degradation and processing of non-coding RNAs. ZCCHC8 contains a CCHC zinc finger motif, which is critical for its RNA-binding capability and for its role in regulating RNA turnover and quality control within the nucleus. By interacting with RNA substrates, ZCCHC8 helps ensure that improperly processed or excess RNA molecules are degraded by the nuclear exosome complex. Inhibitors of ZCCHC8 function by disrupting its ability to bind RNA or by interfering with its role in the NEXT complex, leading to alterations in RNA metabolism and RNA stability.
The mechanisms by which ZCCHC8 inhibitors function can vary depending on their chemical structure. Some inhibitors may directly target the CCHC zinc finger motifs, which are essential for the protein's RNA-binding activity. By destabilizing these motifs, the inhibitors prevent ZCCHC8 from effectively interacting with its RNA substrates, thereby disrupting its role in RNA processing. Other inhibitors may work by interfering with the assembly or stability of the NEXT complex, preventing ZCCHC8 from performing its regulatory functions in conjunction with other proteins in the complex. Additionally, inhibitors might block the interactions between ZCCHC8 and other protein partners required for RNA degradation. By inhibiting ZCCHC8, these compounds provide insight into the broader processes of RNA regulation, RNA degradation, and the mechanisms by which cells maintain RNA homeostasis, shedding light on the fundamental roles of RNA-binding proteins in cellular metabolism.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Amiloride indirectly affects RNA processing by inhibiting RNA helicases, which could influence pathways involving ZCCHC8. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
Pladienolide B targets the spliceosome, potentially impacting pre-mRNA splicing processes where ZCCHC8 may be involved. | ||||||
Spliceostatin A | 391611-36-2 | sc-507481 | 1 mg | $1800.00 | ||
Spliceostatin A inhibits the spliceosome, which may indirectly affect ZCCHC8's role in pre-mRNA splicing. | ||||||
Isoginkgetin | 548-19-6 | sc-507430 | 5 mg | $225.00 | ||
Isoginkgetin is a splicing inhibitor that may indirectly affect ZCCHC8's role in RNA processing. | ||||||
Madrasin | 374913-63-0 | sc-507563 | 100 mg | $750.00 | ||
Madrasin targets spliceosome, potentially influencing ZCCHC8 function in pre-mRNA splicing. | ||||||
Herboxidiene | 142861-00-5 | sc-506378 | 1 mg | $1009.00 | ||
Herboxidiene, a spliceosome inhibitor, could indirectly impact ZCCHC8's role in RNA surveillance and processing. | ||||||
BMH-21 | 896705-16-1 | sc-507460 | 10 mg | $165.00 | ||
BMH-21 indirectly affects RNA polymerase I, potentially influencing ZCCHC8's role in RNA metabolism. | ||||||